The effect of granulocyte colony-stimulating factor (G-CSF), given after transplantation, was studied in 155 patients transplanted with haematopoietic stem cells (HSCT) from HLA-identical sibling donors at Huddinge University Hospital between 1993 and 2001. Only patients with haematological malignancies were included. Conditioning consisted of total-body irradiation in 118 and busulphan in 37 patients. They were all given methotrexate combined with cyclosporine as graft-versus-host disease (GVHD) prophylaxis. Of the 155 patients, 66 (43%) received G-CSF after HSCT. Those given G-CSF had a significantly shorter time to neutrophil engraftment (Po0.001). G-CSF treatment had no effect on erythrocyte transfusions, platelet engraftment and infections. However, patients treated with G-CSF had a significantly higher incidence of grades II-IV acute GVHD than those not given this treatment (34 vs 9%, Po0.001). The multivariate analysis showed that the effect of G-CSF was independent of other known risk factors for grades II-IV acute GVHD. Death from GVHD occurred in four and two cases (P ¼ 0.06) in the two groups, respectively. The cumulative incidences of transplant-related mortality, survival, chronic GVHD, relapse and relapse-free survival were similar in both groups. In conclusion, G-CSF given after HLA-identical sibling HSCT was associated with a higher risk of grades II-IV acute GVHD, but not transplant-related mortality.
Allogeneic haematopoietic stem cell transplantation (HSCT) has become an established treatment for many haematological malignancies and some nonmalignant disorders. [1] [2] [3] Graft-versus-host disease (GVHD) remains a major limitation of successful HSCT and is known to occur because of a complex process in which T cells and cytokines play an important role. [4] [5] [6] [7] [8] The myeloablative therapy before SCT is associated with prolonged pancytopenia, which can result in serious morbidity and life-threatening complications due to infections and bleeding. 9 Haematopoietic growth factors have been increasingly used after HSCT to accelerate myeloid recovery and shorten the high-risk period of bone marrow aplasia. 10 Several trials, analysing the use of granulocyte colonystimulating factor (G-CSF) after related HSCT, have shown a significant acceleration in neutrophil recovery, without an increase in the incidence and severity of GVHD. [11] [12] [13] [14] [15] [16] G-CSF also polarises T cells to produce type-2 cytokines, which may be associated with reduced severity of acute GVHD. [17] [18] [19] [20] We carried out a retrospective trial to evaluate the effect of G-CSF on GVHD and other parameters in patients undergoing HSCT with HLA-identical sibling donors.
Materials and methods

Patients and donors
The study included 155 patients who underwent HSCT with HLA-A, -B and -DR identical sibling donors at Huddinge University Hospital between 1993 and 2001. A total of 108 patients received bone marrow and 47 peripheral blood stem cells: 95 were males and 60 females with a median age of 37 (range 1-60) years. All patients had haematological malignancies. Most of them were in first complete remission (CR) or chronic phase (CP). The demographies of patients and their donors are shown in Table 1 .
Conditioning and GVHD prophylaxis
Cyclophosphamide (Cy) in a dose of 60 mg/kg/day on two consecutive days combined with 10 Gy of total-body irradiation (TBI), with the lungs shielded to receive no more than 9 Gy, was given to 99 patients. Fractionated TBI (3 Gy Â 4) combined with Cy was given to 19 patients, while Cy combined with busulphan (Bu), 4 mg/kg on four consecutive days, was given to 37 patients 21 ( Table 1) . As GVHD prophylaxis all patients received cyclosporine (CsA), combined with a short course of methotrexate (MTX) 22 i.v. in a dose of 15 mg/m 2 on day +1 and 10 mg/ m 2 on days 3, 6 and 11 after SCT. Cyclosporine i.v. was started on day À1 in a dose of 1 mg/kg/day. On day 1 or as soon as the patient could take CsA orally, 3 mg/kg/day was given to maintain the CsA blood trough levels around 100 ng/ml. In the absence of GVHD, the CsA dose was gradually lowered and discontinued after 2-3 months. 23 
Grading and treatment of GVHD
The diagnosis of acute and chronic GVHD was based on clinical symptoms and/or biopsy findings from the skin, liver, gut or oral mucosa. Acute GVHD was graded from 0 to IV, according to previously published criteria. 24 Grade I acute GVHD was treated with 2 mg/kg/day of prednisolone for at least 1 week and thereafter the dose was tapered, depending on the response. 25 In more severe cases, methylprednisolone, ATG, 26 additional MTX or psoralene and ultraviolet light (PUVA) 27, 28 were used.
G-CSF treatment
G-CSF in a dose of 5 mg/kg was given i.v. to 66 patients, but not to 89. It was administered daily by i.v. infusion from day +10 until the patient's absolute neutrophil counts (ANC) reached 40.5 Â 10 9 /l on two consecutive days. 13 
Engraftment
Neutrophil engraftment was defined as ANC 40.5 Â 10 9 /l on two consecutive days. Platelet engraftment was defined as the first day of platelet count X30 Â 10 9 /l for 5 days without platelet transfusions.
Prophylaxis against infections
All patients were kept in reverse isolation from the start of Cy treatment, until neutrophil recovery exceeded 0.5 Â 10 9 /l. Those with HSV-IgG titres X10 000 or a previously recurrent HSV infection were given acyclovir prophylaxis during neutropenia. 29 As gut decontamination, ciprofloxacin, 500 mg twice daily, in combination with oral amphoteracin B was used. Co-trimoxazole was given for 6 months after SCT as prophylaxis against Pneumocystis carinii.
CMV infection and disease were defined according to international guidelines. 30 Patients were monitored for CMV infection using consecutive leucocyte-based polymerase chain reaction (PCR) and pre-emptively treated if increasing CMV DNA levels were found. 31 Patients with CMV infection were treated with ganciclovir or foscarnet. 32 Details about treatment have been published elsewhere. 21, 23, 33, 34 
Statistical analysis
The probabilities of survival, grades II-IV acute GVHD and relapse were calculated with the Kaplan-Meier product-limit method. 35 The differences between the two groups were compared with the log-rank test. 36 Differences in the distribution of patient characteristics were compared with Fisher's exact test or the w 2 -test and corrected with the Yates' method. In the uni-and multivariate risk-factor analysis for grades II-IV acute GVHD, the logistic regression model was used.
37 Only factors at the 10% level from the univariate analysis were assessed in the multivariate (stepwise) analysis. Only patients with acute GVHD or with a survival of at least 30 days without GVHD were included in the study. All measurements of variation were expressed in median and range.
Results
Haematological recovery and transfusions
All patients, except one, had haematological recovery. One non-G-CSF-treated patient died before engraftment because of invasive fungal infection. The median time to reach neutrophil engraftment (40.5 Â 10 9 /l) was 14 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) days in G-CSF-treated patients and 17 days in untreated ones (Po0.001). No significant effect was found on the day of platelet engraftment between the two groups, 18 (10-200) days vs 20 (10-89) days, respectively. G-CSFtreated patients required significantly fewer platelet transfusions, 4 (0-48) units, than untreated ones, 8 (0-49) units (Po0.01). No difference was found between the two groups in the number of erythrocyte and granulocyte transfusions. Likewise, no difference was found in the day of discharge from hospital between the two groups, 22 (15-84) days vs 24 (12-72) days, respectively (P ¼ 0.5).
Infections
The incidence of HSV reactivation was significantly lower in G-CSF-treated patients than in the untreated group, 8% (5/66) vs 19% (17/89) (P ¼ 0.04). The number of pretransplant HSV seropositive patients was higher in the treatment group than in the control group, 83 vs 64% (P ¼ 0.01) ( Table 1 ). The incidence of bacteraemia, CMV infection, CMV disease and VZV infection was similar in the two groups.
Acute and chronic GVHD
The distributions of acute GVHD in both groups are shown in Table 2 . The actuarial probability of grades II-IV acute GVHD was significantly higher in the G-CSF-treated group than in the untreated one, 34 vs 9% (Po0.001, Figure 1 ). The incidences of acute GVHD in G-CSFtreated patients who received PBSC or bone marrow were 39 and 29% (P ¼ 0.5), respectively, vs 0 and 11% among untreated ones (P ¼ 0.3). No difference in chronic GVHD was found between the two groups, and the cumulative incidences at 3 years were 58% in the G-CSF-treated patients and 57% in the untreated group.
Logistic regression analysis
In the univariate logistic regression analysis, significant risk factors for grades II-IV acute GVHD were the use of G-CSF (Po0.001), nucleated cell-dose (Po0.01) and busulphan therapy (Po0.01), while a recipient seropositive for 3-4 herpes viruses (P ¼ 0.09) and PBSC graft (P ¼ 0.09) almost reached significance (Table 3 ). In the multivariate analysis, adjusted for conditioning and nucleated cell-dose, G-CSF was the only factor that significantly correlated with grades II-IV acute GVHD (OR 3.88, CI 1.42-10.6, Po0.01). If G-CSF-was excluded from the analysis, the use of busulphan was the only significant factor. When analysing the G-CSF-treated group separately, busulphan (OR 3.82, CI 1.19-12.2, P ¼ 0.02) and late disease (OR 3.58, CI 1.11-11.6, P ¼ 0.03) were independent risk factors for moderate-to-severe acute GVHD.
Transplantation-related mortality
We found no difference in the cumulative incidence of transplant-related mortality (TRM) between the two groups ( Table 4) . At 100 days, TRM was 8% in the G-CSF group and 5% in the untreated one. At 1 year, the rates were 16 and 18%. At 3 years, TRM was 8% in patients with no acute GVHD, 20% in those with grade I and 37% for those with grade II (P ¼ 0.03 vs no GVHD).
Outcome variables and causes of death
The median follow-up times were 28 (1.2-60) months for the treatment group and 81 (42-105) months in the No G-CSF 9% n=88 P<0.001 Figure 1 Cumulative incidence of grades II-IV acute GVHD in 155
HSCT patients with HLA-identical sibling donors who had or had not been given G-CSF treatment.
untreated one (Po0.001). We found no significant differences in the relapse, relapse-free survival (RFS) or survival rates between the two groups (Table 4) . However, GVHDrelated death tended to occur more in the treatment group than in the controls, 4 vs 2 patients, respectively (P ¼ 0.06). Outcome variables and causes of death in the two groups are shown in Table 4 .
Discussion
In this study, we have found, like others, a significantly shorter time to neutrophil engraftment in G-CSF-treated patients. 11, 14, 16, 38, 39 Despite the shortness of the aplastic phase, we noted no difference in the incidence of early infections or duration of hospital stay after HSCT. Although several trials have been carried out analysing the effect of haematopoietic growth factors on the incidence of infectious complications following SCT, 11, 16, 38, 39 the results are still disputed.
We found that the incidence of HSV reactivation was significantly lower in the G-CSF-treated group, despite the higher number of patients with pretransplant HSV seropositivity in the treatment group, 83 vs 64%, respectively (Table 1) . We give acyclovir prophylaxis only to patients with a high titre of HSV antibodies (X10 000), since 90% of them will develop an HSV infection. 29 No more than 10% of patients with lower HSV titres develop HSV reactivation in our experience, but in the non-G-CSFtreated patients, 19% had an HSV infection. The lower incidence may be due to faster neutrophil engraftment in the G-CSF this group. The need for platelet transfusions was significantly lower in the G-CSF-treated group. However, this difference was mainly contributed to a change in the transfusions policy. Most patients who did not receive G-CSF were given platelet transfusions when platelets were o30 Â 10 9 /l. However, many of the patients given G-CSF were included in a randomised study giving platelet transfusions when platelets were o30 Â 10 9 /l or o10 Â 10 9 /l. This randomised study showed that fewer transfusions were given when the level of o10 Â 10 9 /l was used (Diedrich et al, manuscript) . Patients treated with G-CSF and receiving transfusions when platelets were o30 Â 10 9 /l required a median of 9 (2-81) platelet transfusions, which was about the same (9 (0-57)) as in those not given G-CSF (P ¼ 0.8).
We found no difference in time to reach a platelet count 430 Â 10 9 /l between the two groups, unlike in a study by the International Bone Marrow Transplant Register (IBMTR) in which patients given G-or GM-CSF after transplant took a longer time to reach a platelet count of 420 Â 10 9 /l. 40 This discrepancy may be due to differences in the patient populations or to the fact that G-CSF was started on day 10 after the transplant, while in most other centres G-CSF is started on the day of transplant.
In this retrospective study, we evaluated the incidence of acute GVHD after G-CSF treatment in patients Table 3 Factors affecting acute GVHD, univariate logistic regression analysis undergoing allogeneic matched sibling SCT. Moderateto-severe acute GVHD occurred in 34% of the G-CSFtreated patients and in 9% of the untreated ones (Po0.001). In an earlier study, Berger et al 38 found a trend towards a higher incidence of acute GVHD using G-CSF from the day of transplant. A report from Japan showed that serum soluble interleukin-2 receptor-alpha (sIL-2R) levels were higher in patients who developed acute GVHD during G-CSF administration than in those who developed acute GVHD after it had been stopped. 41 This finding suggests that the administration of G-CSF may aggravate acute GVHD.
Several other studies have also shown that the use of G-CSF does not affect the incidence and severity of GVHD. 11, 13, 38 Pan et al 42 found that pretreatment of donors with G-CSF polarises donor T cells towards production of anti-inflammatory type-2 cytokines, which is associated with a reduction in the severity of acute GVHD after transplantation.
In our study, the higher incidence of acute GVHD in the G-CSF-treated group was mainly due to a higher incidence of grade II acute GVHD, 26 vs 7% (Po0.01), while more severe forms were only slightly increased, 8 vs 2% (P ¼ 0.12).
Despite the higher incidence of grades II-IV acute GVHD, we found no significant difference in the cumulative incidence of TRM between the two groups, 8 vs 5% at 100 days, respectively. This suggests that grade II acute GVHD was not associated with a significantly higher mortality rate than mild acute GVHD in our material. However, the G-CSF-treated group showed a trend towards a higher GVHD-associated mortality rate than the untreated group (P ¼ 0.06).
The incidence of chronic GVHD was similar in the two groups. This may seem surprising because of the correlation between acute and chronic GVHD. [43] [44] [45] Moreover, the data from EBMT and Khouri showed a correlation between G-CSF treatment and chronic GVHD (Ringde´n, Labopin et al and Khouri et al, unpublished observation). More studies are needed to clarify this point.
Chemokines may be involved in GVHD through activation and homing of T cells and other effector cells. 46 A reason for the higher incidence of acute GVHD after G-CSF treatment may be an altered expression of chemokines and chemokine receptors in GVHD effector cells and in the patient's tissue. This needs to be studied further.
We found a higher, but not significant, incidence of acute GVHD in G-CSF-treated patients who had been given PBSC rather than bone marrow as the source of stem cells, 39 vs 29%, respectively. In the untreated group, the incidences were 11% for bone marrow and 0% for PBSC. This may be due to previous treatment of the donor with G-CSF. If the T cells are repeatedly affected by G-CSF, this may amplify the effect.
In animal models, Reddy et al 47 showed that recipients receiving G-CSF mobilised PBSC had a significant reduction in GVHD, which was not changed by giving recipients G-CSF. We could not confirm their findings; indeed we found that G-CSF had the opposite effect. The differences concerning conditioning and post-transplant immunosuppression may have affected the results.
The main question is whether we should treat patients routinely with G-CSF and, if so, which ones? Our data indicate that G-CSF may accelerate neutrophil recovery, but it remains uncertain whether this reduces infections, TRM or time spent in hospital. A previous study from our centre showed that early engraftment was also an important risk factor for acute GVHD 48 in patients not given G-CSF. If G-CSF alone or because of an accelerated rate of neutrophil engraftment triggers or potentiates acute GVHD is unclear. Patients who develop GVHD require much encouragement and medical care, which, together with longer hospitalisation, costs more.
On the basis of these data, we suggest that G-CSF should be given to a selected group of patients who benefit clinically from faster engraftment. This policy has already been introduced in our centre. Since this is a nonrandomised single centre study, further studies are needed to define the role of G-CSF for GVHD.
